Control of renal cell carcinoma brain metastases with cabozantinib following progression on immune checkpoint inhibitor therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Control of renal cell carcinoma brain metastases with cabozantinib following progression on immune checkpoint inhibitor therapy

Published:2021-03 Issue: Volume:3 Page:100060
ISSN:2666-6219
Container-title:Current Problems in Cancer: Case Reports
language:en
Short-container-title:Current Problems in Cancer: Case Reports

Author:

Hong Cierra,Batich Kristen A.^ORCID,Almquist Garland^ORCID,Villa Luis,George Daniel J.,Zhang Tian^ORCID

Publisher

Elsevier BV

Subject

General Medicine

Reference24 articles.

1. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial;Choueiri;Lancet Oncol.,2016

2. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update;Choueiri;Eur. J. Cancer,2018

3. Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis;Crespo;J. Clin. Immunol.,2011

4. A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse;De Groot;J. Clin. Oncol.,2009

5. Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors;Dudek;Clin. Genitourin. Cancer,2013

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking Hope: Anti-VEGFR inhibitors and their potential in glioblastoma treatment;Critical Reviews in Oncology/Hematology;2024-06

2. Aberrant MET Receptor Tyrosine Kinase Signaling in Glioblastoma: Targeted Therapy and Future Directions;Cells;2024-01-25

3. Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence;Clinical Genitourinary Cancer;2023-11

4. An Overview of Systemic Targeted Therapy in Renal Cell Carcinoma, with a Focus on Metastatic Renal Cell Carcinoma and Brain Metastases;Current Issues in Molecular Biology;2023-09-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3